The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for first-line CML treatment and is increasingly used in patients with residual disease or relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.